Rocket One's Hoth Therapeutics Reports Strong HT-001 Efficacy Results, Ends Phase 2a Early and Plans to Pursue Phase 3 to Bring Treatment to Cancer Patients
Rocket One said its biotechnology subsidiary, Hoth Therapeutics, will end the HT-001 Phase 2a trial early after strong interim efficacy results. Hoth plans to seek FDA alignment on a potential pivotal study.
Why it matters — The update concerns a subsidiary’s clinical-trial progress and plans for a possible next-stage study.